



### AMENDMENTS TO THE CLAIMS


1. (ORIGINAL) A method for treating neuropathic pain comprising:  
identifying a subject in need of such treatment; and  
providing the subject with an effective amount of at least one compound that selectively activates the M(1) receptor subtype, whereby one or more symptoms of the neuropathic pain are reduced.
2. (ORIGINAL) The method of claim 1, wherein the subject presents hyperalgesia.
3. (ORIGINAL) The method of claim 1, wherein the subject presents allodynia.
4. (ORIGINAL) The method of claim 1, wherein the neuropathic pain is associated with diabetes, viral infection, irritable bowel syndrome, amputation, cancer, or chemical injury.
5. (ORIGINAL) The method of claim 1, wherein the at least one compound that selectively activates the M(1) receptor subtype does not alleviate acute pain.
6. (ORIGINAL) The method of claim 1, wherein the compound is selected from the group consisting of the compounds of Formulas VII, VIII, and IX:



(VII)



(VIII)



(IX)

7. (ORIGINAL) A method of identifying a compound that alleviates hyperalgesia or allodynia in a subject, comprising:

**Appl. No.** : **10/809,975**  
**Filed** : **March 26, 2004**

providing the subject with at least one muscarinic receptor test compound; and  
determining if the at least one test compound reduces hyperalgesia or allodynia in  
the subject.

8. (ORIGINAL) The method of claim 7, wherein the at least one test compound is  
selective for the M(1) or M(4) but not M(2) or M(3) receptor.

9. (ORIGINAL) The method of claim 7, wherein the at least one test compound is  
selective for the M(1) receptor.

10. (ORIGINAL) The method of claim 7, wherein the hyperalgesia is thermal  
hyperalgesia.

11. (ORIGINAL) The method of claim 7, wherein the allodynia is tactile allodynia.

12-13. (CANCELED)